research use only
Cat.No.S1902
|
In vitro |
DMSO
: 100 mg/mL
(73.78 mM)
Ethanol : 100 mg/mL Water : 30 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1355.37 | Formula | C63H88CoN14O14P |
Storage (From the date of receipt) | Store at 4℃(in the dark) |
|---|---|---|---|---|---|
| CAS No. | 68-19-9 | Download SDF | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | |
| Synonyms | Cobalamin, Cyanocobalamin | SMILES | CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co+3] | ||
Read more about storage stability CAS number SMILES
(data from https://clinicaltrials.gov, updated on 2025-05-13)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06966856 | NOT_YET_RECRUITING | Hypovitaminosis b 12 |
Tanta University |
2026-12-30 | PHASE3 |
| NCT04150042 | RECRUITING | Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation; Pancreas Cancer, Metastatic; Pancreas Cancer, Recurrent; Pancreas Cancer; Stage IV Pancreatic Cancer; Stage 4 Pancreatic Cancer |
General Oncology, Inc. |
2021-01-13 | PHASE1 |
| NCT07697196 | NOT_YET_RECRUITING | HPV Infection; HPV Integration; HPV Disease; HPV Genital Infection; HPV Persistence; Low Grade Squamous Intraepithelial Lesions of the Cervix |
IRCCS San Raffaele |
2026-07 | |
| NCT07344337 | NOT_YET_RECRUITING | HPV Infection; Infertilities |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2026-03 | |
| NCT07320183 | NOT_YET_RECRUITING | HPV - Anogenital Human Papilloma Virus Infection; Infertilities |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2026-03-01 | |
| NCT05796401 | RECRUITING | Psychosis |
Centre Hospitalier St Anne |
2023-12-15 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.